Compare Target Corporation (TGT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Target Corporation vs TG Therapeutics Inc — how do they compare? Target Corporation trades at $158.01 (market cap $73.92B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Target Corporation is far larger — about 8.7× TG Therapeutics Inc's market cap, and Target Corporation pays a 2.85% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGT | TGTX | |
|---|---|---|
Market Cap | $73.92B | $8.53B |
Sector | Consumer Cyclical | Health |
52-Week High | $169.90 | $59.06 |
52-Week Low | $83.68 | $26.94 |
Enterprise Value | $87.20B | $8.74B |
Dividend Yield | 2.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Target (TGT) trades at $162.71, down 1.05% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong profitability with a 26.41% ROE and 4.08% net margin, supported by three consecutive quarterly EPS beats. Revenue remains stable near $107B, while valuation ratios like P/E of 16.88 and P/S of 0.69 suggest reasonable pricing. Recent news highlights CEO Michael Fiddelke's turnaround success, with shares surging over 70% year-to-date.
Outlook is positive with analyst consensus at $166.67 and 47% buy ratings, but risks include competitive retail pressures and margin compression. The dividend yield of approximately 2.85% adds income appeal, though valuation expansion from recent gains warrants caution amid economic uncertainty.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
